George A Alexiou1, Anastasia Zikou2, Spyridon Tsiouris3, Anna Goussia4, Paraskevi Kosta2, Athanasios Papadopoulos3, Spyridon Voulgaris5, Pericles Tsekeris6, Athanasios P Kyritsis7, Andreas D Fotopoulos3, Maria I Argyropoulou2. 1. Department of Neurosurgery, University Hospital of Ioannina, Ioannina, Greece. Electronic address: alexiougrg@yahoo.gr. 2. Department of Radiology, University Hospital of Ioannina, Ioannina, Greece. 3. Department of Nuclear Medicine, University Hospital of Ioannina, Ioannina, Greece. 4. Department of Pathology, University Hospital of Ioannina, Ioannina, Greece. 5. Department of Neurosurgery, University Hospital of Ioannina, Ioannina, Greece. 6. Department of Radiation Therapy, University Hospital of Ioannina, Ioannina, Greece. 7. Department of Neurology, University Hospital of Ioannina, Ioannina, Greece.
Abstract
INTRODUCTION: Treatment induced necrosis is a relatively frequent finding in patients treated for high-grade glioma. Differentiation by imaging modalities between glioma recurrence and treatment induced necrosis is not always straightforward. This is a comparative study of diffusion tensor imaging (DTI), dynamic susceptibility contrast MRI and (99m)Tc-Tetrofosmin brain single-photon emission computed tomography (SPECT) for differentiation of recurrent glioma from treatment induced necrosis. METHODS: A prospective study was made of 30 patients treated for high-grade glioma who had suspected recurrent tumor on follow-up MRI. All had been treated by surgical resection of the tumor followed by standard postoperative radiotherapy with chemotherapy. No residual tumor had been found on brain imaging immediately after the initial treatment. All the patients were studied with dynamic susceptibility contrast brain MRI and, within a week, (99m)Tc-Tetrofosmin brain SPECT. RESULTS: Both (99m)Tc-Tetrofosmin brain SPECT and dynamic susceptibility contrast MRI could discriminate between tumor recurrence and treatment induced necrosis with 100% sensitivity and 100% specificity. An apparent diffusion coefficient (ADC) ratio cut-off value of 1.27 could differentiate recurrence from treatment induced necrosis with 65% sensitivity and 100% specificity and a fractional anisotropy (FA) ratio cut-off value of 0.47 could differentiate recurrence from treatment induced necrosis with 57% sensitivity and 100% specificity. A significant correlation was demonstrated between (99m)Tc-Tetrofosmin uptake ratio and rCBV (P=0.003). CONCLUSIONS: Dynamic susceptibility contrast MRI and brain SPECT with (99m)Tc-Tetrofosmin had the same accuracy and may be used to detect recurrent tumor following treatment for glioma. DTI also showed promise for the detection of recurrent tumor, but was inferior to both dynamic susceptibility contrast MRI and brain SPECT.
INTRODUCTION: Treatment induced necrosis is a relatively frequent finding in patients treated for high-grade glioma. Differentiation by imaging modalities between glioma recurrence and treatment induced necrosis is not always straightforward. This is a comparative study of diffusion tensor imaging (DTI), dynamic susceptibility contrast MRI and (99m)Tc-Tetrofosmin brain single-photon emission computed tomography (SPECT) for differentiation of recurrent glioma from treatment induced necrosis. METHODS: A prospective study was made of 30 patients treated for high-grade glioma who had suspected recurrent tumor on follow-up MRI. All had been treated by surgical resection of the tumor followed by standard postoperative radiotherapy with chemotherapy. No residual tumor had been found on brain imaging immediately after the initial treatment. All the patients were studied with dynamic susceptibility contrast brain MRI and, within a week, (99m)Tc-Tetrofosmin brain SPECT. RESULTS: Both (99m)Tc-Tetrofosmin brain SPECT and dynamic susceptibility contrast MRI could discriminate between tumor recurrence and treatment induced necrosis with 100% sensitivity and 100% specificity. An apparent diffusion coefficient (ADC) ratio cut-off value of 1.27 could differentiate recurrence from treatment induced necrosis with 65% sensitivity and 100% specificity and a fractional anisotropy (FA) ratio cut-off value of 0.47 could differentiate recurrence from treatment induced necrosis with 57% sensitivity and 100% specificity. A significant correlation was demonstrated between (99m)Tc-Tetrofosmin uptake ratio and rCBV (P=0.003). CONCLUSIONS: Dynamic susceptibility contrast MRI and brain SPECT with (99m)Tc-Tetrofosmin had the same accuracy and may be used to detect recurrent tumor following treatment for glioma. DTI also showed promise for the detection of recurrent tumor, but was inferior to both dynamic susceptibility contrast MRI and brain SPECT.
Authors: William R Masch; Page I Wang; Thomas L Chenevert; Larry Junck; Christina Tsien; Jason A Heth; Pia C Sundgren Journal: Acad Radiol Date: 2016-02-23 Impact factor: 3.173
Authors: Robert H Press; Jim Zhong; Saumya S Gurbani; Brent D Weinberg; Bree R Eaton; Hyunsuk Shim; Hui-Kuo G Shu Journal: Neurosurgery Date: 2019-08-01 Impact factor: 4.654
Authors: P Alcaide-Leon; J Cluceru; J M Lupo; T J Yu; T L Luks; T Tihan; N A Bush; J E Villanueva-Meyer Journal: AJNR Am J Neuroradiol Date: 2020-10-15 Impact factor: 3.825
Authors: Sean P Devan; Xiaoyu Jiang; Guozhen Luo; Jingping Xie; James D Quirk; John A Engelbach; Hannah Harmsen; Eliot T McKinley; Jing Cui; Zhongliang Zu; Albert Attia; Joel R Garbow; John C Gore; Colin D McKnight; Austin N Kirschner; Junzhong Xu Journal: Cancer Res Date: 2022-10-04 Impact factor: 13.312
Authors: Julia Cluceru; Sarah J Nelson; Qiuting Wen; Joanna J Phillips; Anny Shai; Annette M Molinaro; Paula Alcaide-Leon; Marram P Olson; Devika Nair; Marisa LaFontaine; Pranathi Chunduru; Javier E Villanueva-Meyer; Soonmee Cha; Susan M Chang; Mitchel S Berger; Janine M Lupo Journal: Neuro Oncol Date: 2020-10-14 Impact factor: 13.029
Authors: Eike Steidl; Karl-Josef Langen; Sarah Abu Hmeidan; Nenad Polomac; Christian P Filss; Norbert Galldiks; Philipp Lohmann; Fee Keil; Katharina Filipski; Felix M Mottaghy; Nadim Jon Shah; Joachim P Steinbach; Elke Hattingen; Gabriele D Maurer Journal: Eur J Nucl Med Mol Imaging Date: 2020-11-26 Impact factor: 9.236